However, the considerations in choosing BRAF/MEK or anti-PD-1 as first-line therapy in the advanced melanoma setting (i.e., relatively quick anti-tumor effect of BRAK/MEK inhibitors versus less acquired resistance in case of immunotherapy) can be different in the adjuvant setting. This evidence concerns the gene MAP2K7 and neoplasm.